Cure My Disease

Don't miss your cure!

 Log in / Sign up

Why is endometrial cancer often advanced in brazil? a new study digs into the data

NCT ID NCT06014580

Knowledge-focused Sponsor: Latin American Cooperative Oncology Group Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 27, 2026 · Last updated Aug 28, 2026 · Updated 1 time

Summary

This observational study will examine the molecular and epidemiological characteristics of endometrial cancer in Brazil, focusing on women diagnosed between 2016 and 2019. Researchers will analyze tumor samples for genetic mutations and biomarkers, and collect data on demographics, treatment patterns, and outcomes. The goal is to understand why advanced disease is common and to generate knowledge that could guide future clinical trials and improve care for this population.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could reveal why endometrial cancer is often advanced in Brazil and point toward targeted therapies and better treatment strategies for this population.
What could go wrong
This is an observational study, so it will not test any new treatment. The findings may not apply beyond the Brazilian population studied, and the data depends on the quality of medical records and tumor samples.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

276 people

The number who actually took part.

Started

Nov 2023

Finished

Oct 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Women diagnosed with endometrial cancer between January 2016 and December 2019 at participating research sites.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Women ≥18 years * Histological diagnosis of endometrial carcinoma. * Diagnosis of endometrial cancer between January 2016 and December 2019. * FIGO (International Federation of Gynecology and Obstetrics, 2018) Stage I - IV. * Site and investigator with access to a medical record chart from which data can be abstracted. * Presence of a sample of tumor tissue (primary tumor or metastasis) available for biomarker testing. Exclusion Criteria: * Noninvasive endometrial cancer. * Patients with a history of concurrent or previously treated non-endometrial malignancies except for appropriately treated 1) non -metastatic non-melanoma skin cancer and/or 2) non-metastatic low-grade thyroid tumors and/or 3) in situ carcinomas, including cervix, colon, and skin. * Nonepithelial histology (leiomyosarcoma, adenosarcoma, endometrial stromal sarcoma, undifferentiated sarcoma, or other mesenchymal tumors.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Endometrial cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

endometrial cancer endometrial carcinoma endometrium neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Endometrial cancer

Contacts and locations

Locations

  • BP - A Beneficência Portuguesa de São Paulo

    São Paulo, São Paulo, 01323-030, Brazil

  • Clinica Prognóstica - Centro de Pesquisa Clínica Onconeo

    Campo Grande, Mato Grosso do Sul, 79.002-061, Brazil

  • Hospital Evangélico de Cachoeiro de Itapemirim - Centro de Pesquisas Clínicas em Oncologia (CPCO)

    Cachoeiro de Itapemirim, Espírito Santo, 29.308-065, Brazil

  • Hospital Napoleão Laureano

    João Pessoa, Paraíba, 58013-140, Brazil

  • Hospital de Oncologia do Maranhão Dr. Tarquínio Lopes Filho

    São Luís, Maranhão, 65015-460, Brazil

  • ICC - Instituto do Câncer do Ceará

    Fortaleza, Ceará, 60.430-230, Brazil

  • INCA - Instituto Nacional de Câncer

    Rio de Janeiro, Rio de Janeiro, 20.230-130, Brazil

  • Instituto do Câncer Brasil - Unidade Três Lagoas

    Três Lagoas, Mato Grosso do Sul, 79.601-001, Brazil

  • Santa Casa de Misericórdia de Feira de Santana

    Feira de Santana, Estado de Bahia, Brazil

  • UOPECCAN - Hospital do Câncer de Cascavel

    Cascavel, Santa Catarina, 85.806-300, Brazil

More trials for these conditions

Other studies related to the condition(s) this trial covers.